MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Temuterkib

CAS No. : 1951483-29-6

MCE 站：Temuterkib

产品活性：Temuterkib (LY3214996) 是高效的选择性 ERK1 和 ERK2 抑制剂，IC₅₀ 为 5 nM。Temuterkib 作用于 BRAF 和 RAS 突变癌细胞系中，有效抑制 p-RSK1。Temuterkib 在 MAPK 途径改变的癌症模型中具有强大的抗肿瘤活性。

研究领域：MAPK/ERK Pathway  |  Stem Cell/Wnt

作用靶点：ERK

In Vitro: Temuterkib is a highly selective inhibitor of ERK1 and ERK2, with IC₅₀ of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines. In an unbiased tumor cell panel sensitivity profiling for inhibition of cell proliferation, tumor cells with MAPK pathway alterations including BRAF, NRAS or KRAS mutation are generally sensitivity to Temuterkib.

In Vivo: In tumor xenograft models, Temuterkib inhibits PD biomarker phospho-p90RSK1 in tumors and the PD effects are correlated with compound exposures and anti-tumor activities. Temuterkib shows either similar or superior anti-tumor activity as compared to other published ERK inhibitors in BRAF or RAS mutant cell lines and xenograft models. Oral administration of single-agent Temuterkib significantly inhibits tumor growth in vivo and is well tolerated in BRAF or NRAS mutant melanoma, BRAF or KRAS mutant colorectal, lung and pancreatic cancer xenografts or PDX models. Therefore, Temuterkib can be tailored for treatment of cancers with MAPK pathway alteration. In addition, Temuterkib has anti-tumor activity in a PLX4032-resistant A375 melanoma xenograft model due to MAPK reactivation, may have potential for treatment of melanoma patients who have failed BRAF therapies. More importantly, Temuterkib can be combined with investigational and approved agents in preclinical models, particularly KRAS mutant models. Combination treatment of Temuterkib and CDK4/6 inhibitor abemaciclib is well tolerated and results in potent tumor growth inhibition or regression in multiple in vivo cancer models, including KRAS mutant colorectal and non-small cell lung cancers.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Angiogenesis Related Compound Library  |  PD98059  |  SCH772984  |  TBHQ  |  Tauroursodeoxycholate sodium  |  Ravoxertinib  |  Honokiol  |  Ulixertinib  |  Astragaloside IV  |  Piperlongumine  |  Lidocaine  |  BIX02189  |  FR 180204  |  XMD8-92  |  AX-15836  |  Urolithin B  |  Pluripotin  |  MK-8353  |  KO-947  |  LM22B-10  |  Tizaterkib  |  VX-11e  |  Mogrol  |  C16-PAF  |  trans-Zeatin  |  Pachymic acid  |  Pamoic acid disodium

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。